0001752724-21-261569.txt : 20211129 0001752724-21-261569.hdr.sgml : 20211129 20211129094645 ACCESSION NUMBER: 0001752724-21-261569 CONFORMED SUBMISSION TYPE: NPORT-P PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211129 PERIOD START: 20211231 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LOOMIS SAYLES FUNDS II CENTRAL INDEX KEY: 0000872649 IRS NUMBER: 043113285 STATE OF INCORPORATION: MA FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: NPORT-P SEC ACT: 1940 Act SEC FILE NUMBER: 811-06241 FILM NUMBER: 211453243 BUSINESS ADDRESS: STREET 1: 888 BOYLSTON STREET STREET 2: 8TH FLOOR CITY: BOSTON STATE: MA ZIP: 02199 BUSINESS PHONE: 617-449-2810 MAIL ADDRESS: STREET 1: 888 BOYLSTON STREET STREET 2: 8TH FLOOR CITY: BOSTON STATE: MA ZIP: 02199 FORMER COMPANY: FORMER CONFORMED NAME: LOOMIS SAYLES FUNDS I DATE OF NAME CHANGE: 20031119 FORMER COMPANY: FORMER CONFORMED NAME: LOOMIS SAYLES FUNDS DATE OF NAME CHANGE: 20031015 FORMER COMPANY: FORMER CONFORMED NAME: LOOMIS SAYLES FUNDS II DATE OF NAME CHANGE: 20030718 0000872649 S000070337 Loomis Sayles International Growth Fund C000223746 Class Y LIGYX C000223747 Class A LIGGX C000223748 Class C LIGCX C000223749 Class N LIGNX NPORT-P 1 primary_doc.xml NPORT-P false 0000872649 XXXXXXXX S000070337 C000223746 C000223749 C000223748 C000223747 LOOMIS SAYLES FUNDS II 811-06241 0000872649 5493007QOEDY6IHOTU14 888 BOYLSTON STREET Suite 800 BOSTON 02199-8197 617-449-2822 Loomis Sayles International Growth Fund S000070337 549300B3EC2I33ZC7N86 2021-12-31 2021-09-30 N 23879957.83 60901.70 23819056.13 0.00000000 0.00000000 0.00000000 0.00000000 0.00000000 0.00000000 0.00000000 0.00000000 0.00000000 0.00000000 0.00000000 0.00000000 0.00000000 20145.05000000 N Kweichow Moutai Co Ltd N/A Kweichow Moutai Co Ltd 000000000 3100.00000000 NS 876927.84000000 3.681622962781 Long EC CORP CN N 2 N N N Schlumberger NV 213800ZUA17OK3QLGM62 Schlumberger NV 000000000 10030.00000000 NS USD 297289.20000000 1.248114947869 Long EC CORP CW N 1 N N N Core Laboratories NV 724500MDYY5VBSAF5W50 Core Laboratories NV 000000000 4321.00000000 NS USD 119907.75000000 0.503411005648 Long EC CORP NL N 1 N N N SAP SE 529900D6BF99LW9R2E68 SAP SE 000000000 5548.00000000 NS 750251.19000000 3.149793954492 Long EC CORP DE N 2 N N N Novo Nordisk A/S 549300DAQ1CVT6CXN342 Novo Nordisk A/S 000000000 8249.00000000 NS 795116.96000000 3.338154776832 Long EC CORP DK N 2 N N N Dali Foods Group Co Ltd 52990093PPQC644N7T38 Dali Foods Group Co Ltd 000000000 456500.00000000 NS 275612.90000000 1.157110922010 Long EC CORP KY N 1 N N N Reckitt Benckiser Group PLC 5493003JFSMOJG48V108 Reckitt Benckiser Group PLC 000000000 9470.00000000 NS 743964.95000000 3.123402312583 Long EC CORP GB N 2 N N N Sodexo SA 969500LCBOG12HXPYM84 Sodexo SA 000000000 7379.00000000 NS 644892.36000000 2.707463958606 Long EC CORP FR N 2 N N N Roche Holding AG 549300U41AUUVOAAOB37 Roche Holding AG 000000000 3830.00000000 NS 1397834.15000000 5.868553910662 Long EC CORP CH N 2 N N N Alibaba Group Holding Ltd 5493001NTNQJDH60PM02 Alibaba Group Holding Ltd 01609W102 6367.00000000 NS USD 942634.35000000 3.957479863413 Long EC CORP KY N 1 N N N NXP Semiconductors NV 724500M9BY5293JDF951 NXP Semiconductors NV 000000000 3595.00000000 NS USD 704152.65000000 2.956257570228 Long EC CORP NL N 1 N N N Adyen NV 724500973ODKK3IFQ447 Adyen NV 000000000 509.00000000 NS 1422839.12000000 5.973532755598 Long EC CORP NL N 2 N N N CRISPR Therapeutics AG 506700O6IRRIQLT3W370 CRISPR Therapeutics AG 000000000 5480.00000000 NS USD 613376.40000000 2.575149899527 Long EC CORP CH N 1 N N N Nestle SA KY37LUS27QQX7BB93L28 Nestle SA 000000000 6811.00000000 NS 820657.51000000 3.445382157550 Long EC CORP CH N 2 N N N Galaxy Entertainment Group Ltd 549300ZSEBV3HR826S10 Galaxy Entertainment Group Ltd 000000000 39000.00000000 NS 200110.21000000 0.840126531075 Long EC CORP HK N 2 N N N WiseTech Global Ltd 254900VE3AF301Q85K83 WiseTech Global Ltd 000000000 33026.00000000 NS 1252452.28000000 5.258194418638 Long EC CORP AU N 2 N N N Unilever PLC 549300MKFYEKVRWML317 Unilever PLC 000000000 10119.00000000 NS 546588.94000000 2.294754825786 Long EC CORP GB N 2 N N N FANUC Corp 529900QTSW745LOKW705 FANUC Corp 000000000 4100.00000000 NS 898973.61000000 3.774178141625 Long EC CORP JP N 2 N N N Yum China Holdings Inc 529900DO9BYZ7VA3K502 Yum China Holdings Inc 98850P109 12201.00000000 NS USD 709000.11000000 2.976608754479 Long EC CORP US N 1 N N N Anheuser-Busch InBev SA/NV 5493008H3828EMEXB082 Anheuser-Busch InBev SA/NV 000000000 8040.00000000 NS 456007.78000000 1.914466205172 Long EC CORP BE N 2 N N N Budweiser Brewing Co APAC Ltd 549300YF1MR4GTF18132 Budweiser Brewing Co APAC Ltd 000000000 57800.00000000 NS 146814.30000000 0.616373290355 Long EC CORP KY N 2 N N N Ambev SA 549300TH5Q6VRP8OT012 Ambev SA 02319V103 313255.00000000 NS USD 864583.80000000 3.629798742994 Long EC CORP BR N 1 N N N Trip.com Group Ltd 2549004RMYDSRQL4KW41 Trip.com Group Ltd 89677Q107 24101.00000000 NS USD 741105.75000000 3.111398478408 Long EC CORP KY N 1 N N N Experian PLC 635400RXXHHYT1JTSZ26 Experian PLC 000000000 17805.00000000 NS 745853.70000000 3.131331887918 Long EC CORP JE N 2 N N N Vipshop Holdings Ltd 549300I9F52K06HPZX60 Vipshop Holdings Ltd 92763W103 41375.00000000 NS USD 460917.50000000 1.935078776776 Long EC CORP KY N 1 N N N Baidu Inc 254900AL64IANZYI1E02 Baidu Inc 056752108 4161.00000000 NS USD 639753.75000000 2.685890433728 Long EC CORP KY N 1 N N N Unicharm Corp 353800UQ4BZIJTAQEG85 Unicharm Corp 000000000 5300.00000000 NS 234853.56000000 0.985990203466 Long EC CORP JP N 2 N N N Diageo PLC 213800ZVIELEA55JMJ32 Diageo PLC 000000000 6459.00000000 NS 312712.55000000 1.312867093864 Long EC CORP GB N 2 N N N EssilorLuxottica SA 549300M3VH1A3ER1TB49 EssilorLuxottica SA 000000000 2482.00000000 NS 474292.98000000 1.991233310889 Long EC CORP FR N 2 N N N MercadoLibre Inc 549300DKPDN9M5S8GB14 MercadoLibre Inc 58733R102 1051.00000000 NS USD 1765049.40000000 7.410240734841 Long EC CORP US N 1 N N N Novartis AG 5493007HIVTX6SY6XD66 Novartis AG 000000000 12727.00000000 NS 1043603.25000000 4.381379532019 Long EC CORP CH N 2 N N N Tencent Holdings Ltd 254900N4SLUMW4XUYY11 Tencent Holdings Ltd 000000000 22000.00000000 NS 1313371.77000000 5.513953881429 Long EC CORP KY N 2 N N N Fixed Income Clearing Corp 549300H47WTHXPU08X20 FIXED INC CLEARING CORP.REPO 000000000 609154.21000000 PA USD 609154.21000000 2.557423798303 Long RA CORP US N 2 Repurchase N 0.00000000 2021-10-01 624600.00000000 USD 621379.56000000 USD UST N N N 2021-10-28 LOOMIS SAYLES FUNDS II John Sgroi John Sgroi Assistant Treasurer XXXX NPORT-EX 2 NPORT_48AR_90497244_0921.htm HTML

PORTFOLIO OF INVESTMENTS – as of September 30, 2021 (Unaudited)

Loomis Sayles International Growth Fund

 

Shares

  

Description

   Value (†)  

Common Stocks – 97.4% of Net Assets

 

   Argentina – 7.4%

 

1,051

   MercadoLibre, Inc.(a)    $    1,765,050  
     

 

 

 
   Australia – 5.3%

 

33,026

   WiseTech Global Ltd.      1,252,452  
     

 

 

 
   Belgium – 1.9%

 

8,040

   Anheuser-Busch InBev S.A.      456,008  
     

 

 

 
   Brazil – 3.6%

 

313,255

   Ambev S.A., ADR      864,584  
     

 

 

 
   China – 28.6%

 

6,367

   Alibaba Group Holding Ltd., Sponsored ADR(a)      942,634  

4,161

   Baidu, Inc., Sponsored ADR(a)      639,754  

57,800

   Budweiser Brewing Co. APAC Ltd., 144A      146,814  

    456,500

   Dali Foods Group Co. Ltd., 144A      275,613  

3,100

   Kweichow Moutai Co. Ltd., Class A      876,928  

3,595

   NXP Semiconductors NV      704,153  

22,000

   Tencent Holdings Ltd.      1,313,372  

24,101

   Trip.com Group Ltd., ADR(a)      741,106  

41,375

   Vipshop Holdings Ltd., ADR(a)      460,917  

12,201

   Yum China Holdings, Inc.      709,000  
     

 

 

 
        6,810,291  
     

 

 

 
   Denmark – 3.3%

 

8,249

   Novo Nordisk A/S, Class B      795,117  
     

 

 

 
   France – 4.7%

 

2,482

   EssilorLuxottica S.A.      474,293  

7,379

   Sodexo S.A.(a)      644,893  
     

 

 

 
        1,119,186  
     

 

 

 
   Germany – 3.1%

 

5,548

   SAP SE      750,251  
     

 

 

 
   Japan – 4.8%

 

4,100

   FANUC Corp.      898,974  

5,300

   Unicharm Corp.      234,853  
     

 

 

 
        1,133,827  
     

 

 

 
   Macau – 0.8%

 

39,000

   Galaxy Entertainment Group Ltd.(a)      200,110  
     

 

 

 
   Netherlands – 6.0%

 

509

   Adyen NV, 144A(a)      1,422,839  
     

 

 

 
   Switzerland – 16.3%

 

5,480

   CRISPR Therapeutics AG(a)      613,376  

6,811

   Nestle S.A., (Registered)      820,658  

12,727

   Novartis AG, (Registered)      1,043,603  


Shares

  

Description

   Value (†)  

Common Stocks – continued

 

   Switzerland – continued

 

3,830

   Roche Holding AG    $    1,397,834  
     

 

 

 
        3,875,471  
     

 

 

 
   United Kingdom – 9.9%

 

6,459

   Diageo PLC      312,712  

17,805

   Experian PLC      745,854  

9,470

   Reckitt Benckiser Group PLC      743,965  

10,119

   Unilever PLC      546,589  
     

 

 

 
        2,349,120  
     

 

 

 
   United States – 1.7%

 

4,321

   Core Laboratories NV      119,908  

10,030

   Schlumberger NV      297,289  
     

 

 

 
        417,197  
     

 

 

 
  

Total Common Stocks

(Identified Cost $24,697,196)

     23,211,503  
     

 

 

 

Principal

Amount

 

Short-Term Investments – 2.6%

 

$    609,154

  

Tri-Party Repurchase Agreement with Fixed Income Clearing Corporation, 9/30/2021 at 0.000% to be repurchased at $609,154 on 10/01/2021 collateralized by $624,600 U.S. Treasury Note, 1.250% due 9/30/2028 valued at $621,380 including accrued interest(b)

(Identified Cost $609,154)

     609,154  
     

 

 

 
  

Total Investments – 100.0%

(Identified Cost $25,306,350)

     23,820,657  
   Other assets less liabilities – (0.0)%      (1,332
     

 

 

 
   Net Assets – 100.0%    $ 23,819,325  
     

 

 

 


(†)

Fund securities and other investments are valued at market value based on market quotations obtained or determined by independent pricing services recommended by the adviser and approved by the Board of Trustees. Fund securities and other investments for which market quotations are not readily available are valued at fair value as determined in good faith by the adviser pursuant to procedures approved by the Board of Trustees, as described below. Market value is determined as follows:

Listed equity securities (including shares of closed-end investment companies and exchange-traded funds) are valued at the last sale price quoted on the exchange where they are traded most extensively or, if there is no reported sale during the day, the closing bid quotation as reported by an independent pricing service. Securities traded on the NASDAQ Global Select Market, NASDAQ Global Market and NASDAQ Capital Market are valued at the NASDAQ Official Closing Price (“NOCP”), or if lacking an NOCP, at the most recent bid quotations on the applicable NASDAQ Market. Unlisted equity securities (except unlisted preferred equity securities) are valued at the last sale price quoted in the market where they are traded most extensively or, if there is no reported sale during the day, the closing bid quotation as reported by an independent pricing service. If there is no last sale price or closing bid quotation available, unlisted equity securities will be valued using evaluated bids furnished by an independent pricing service, if available.

In some foreign markets, an official close price and a last sale price may be available from the foreign exchange or market. In those cases, the official close price is used.

Debt securities and unlisted preferred equity securities are valued based on evaluated bids furnished to the Fund by an independent pricing service or bid prices obtained from broker-dealers.

Broker-dealer bid prices may be used to value debt and unlisted equity securities where an independent pricing service is unable to price a security or where an independent pricing service does not provide a reliable price for the security.

Fund securities and other investments for which market quotations are not readily available are valued at fair value as determined in good faith by the adviser pursuant to procedures approved by the Board of Trustees. The Fund may also value securities and other investments at fair value in other circumstances such as when extraordinary events occur after the close of a foreign market but prior to the close of the New York Stock Exchange. This may include situations relating to a single issuer (such as a declaration of bankruptcy or a delisting of the issuer’s security from the primary market on which it has traded) as well as events affecting the securities markets in general (such as market disruptions or closings and significant fluctuations in U.S. and/or foreign markets). When fair valuing its securities or other investments, the Fund may, among other things, use modeling tools or other processes that may take into account factors such as securities or other market activity and/or significant events that occur after the close of the foreign market and before the time the Fund’s net asset value (“NAV”) is calculated. Fair value pricing may require subjective determinations about the value of a security, and fair values used to determine the Fund’s NAV may differ from quoted or published prices, or from prices that are used by others, for the same securities. In addition, the use of fair value pricing may not always result in adjustments to the prices of securities held by the Fund.

As of September 30, 2021, securities held by the Fund were fair valued as follows:

 

Equity securities1

   Percentage of Net Assets  

$ 15,078,119

     63.3

 

1 

Certain foreign equity securities were fair valued pursuant to procedures approved by the Board of Trustees as events occurring after the close of the foreign market were believed to materially affect the value of those securities.

The books and records of the Fund are maintained in U.S. dollars. The values of securities, currencies and other assets and liabilities denominated in currencies other than U.S. dollars are translated into U.S. dollars based upon foreign exchange rates prevailing at the end of the period.

 

(a)

Non-income producing security.

 

(b)

The Fund may enter into repurchase agreements, under the terms of a Master Repurchase Agreement, under which the Fund acquires securities as collateral and agrees to resell the securities at an agreed upon time and at an agreed upon price. It is the Fund’s policy that the market value of the collateral for repurchase agreements be at least equal to 102% of the repurchase price, including interest. Certain repurchase agreements are tri-party arrangements whereby the collateral is held in a segregated account for the benefit of the Fund and on behalf of the counterparty. Repurchase agreements could involve certain risks in the event of default or insolvency of the counterparty, including possible delays or restrictions upon the Fund’s ability to dispose of the underlying securities. As of September 30, 2021, the Fund had an investment in a repurchase agreement for which the value of the related collateral exceeded the value of the repurchase agreement.

 

144A

All or a portion of these securities are exempt from registration under Rule 144A of the Securities Act of 1933. These securities may be resold in transactions exempt from registration, normally to qualified institutional buyers. At September 30, 2021, the value of Rule 144A holdings amounted to $1,845,266 or 7.7% of net assets.

 

ADR

An American Depositary Receipt is a certificate issued by a custodian bank representing the right to receive securities of the foreign issuer described. The values of ADRs may be significantly influenced by trading on exchanges not located in the United States.


Fair Value Measurements

In accordance with accounting standards related to fair value measurements and disclosures, the Fund has categorized the inputs utilized in determining the value of the Fund’s assets or liabilities. These inputs are summarized in the three broad levels listed below:

 

   

Level 1 — quoted prices in active markets for identical assets or liabilities;

 

   

Level 2 — prices determined using other significant inputs that are observable either directly, or indirectly through corroboration with observable market data (which could include quoted prices for similar assets or liabilities, interest rates, credit risk, etc.); and

 

   

Level 3 — prices determined using significant unobservable inputs when quoted prices or observable inputs are unavailable such as when there is little or no market activity for an asset or liability (unobservable inputs reflect the Fund’s own assumptions in determining the fair value of assets or liabilities and would be based on the best information available).

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.


The following is a summary of the inputs used to value the Fund’s investments as of September 30, 2021, at value:

Asset Valuation Inputs

 

Description

   Level 1      Level 2      Level 3      Total  

Common Stocks

           

Australia

   $ —        $ 1,252,452      $  —        $ 1,252,452  

Belgium

     —          456,008        —          456,008  

China

     4,473,177        2,337,114        —          6,810,291  

Denmark

     —          795,117        —          795,117  

France

     —          1,119,186        —          1,119,186  

Germany

     —          750,251        —          750,251  

Japan

     —          1,133,827        —          1,133,827  

Macau

     —          200,110        —          200,110  

Netherlands

     —          1,422,839        —          1,422,839  

Switzerland

     613,376        3,262,095        —          3,875,471  

United Kingdom

     —          2,349,120        —          2,349,120  

All Other Common Stocks*

     3,046,831        —          —          3,046,831  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total Common Stocks

     8,133,384        15,078,119        —          23,211,503  
  

 

 

    

 

 

    

 

 

    

 

 

 

Short-Term Investments

     —          609,154        —          609,154  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

   $ 8,133,384      $ 15,687,273      $ —        $ 23,820,657  
  

 

 

    

 

 

    

 

 

    

 

 

 

 

*

Details of the major categories of the Fund’s investments are reflected within the Portfolio of Investments.


Industry Summary at September 30, 2021 (Unaudited)

 

Pharmaceuticals

     13.6

Internet & Direct Marketing Retail

     13.3  

Beverages

     11.1  

Hotels, Restaurants & Leisure

     9.6  

Software

     8.4  

Interactive Media & Services

     8.2  

IT Services

     6.0  

Food Products

     4.6  

Household Products

     4.1  

Machinery

     3.8  

Professional Services

     3.2  

Semiconductors & Semiconductor Equipment

     2.9  

Biotechnology

     2.6  

Personal Products

     2.3  

Textiles, Apparel & Luxury Goods

     2.0  

Other Investments, less than 2% each

     1.7  

Short-Term Investments

     2.6  
  

 

 

 

Total Investments

     100.0  

Other assets less liabilities

     (0.0 )* 
  

 

 

 

Net Assets

     100.0
  

 

 

 

 

*

Less than 0.1%


Currency Exposure Summary at September 30, 2021 (Unaudited)

 

United States Dollar

     35.5

Euro

     18.0  

Swiss Franc

     13.7  

Hong Kong Dollar

     8.1  

British Pound

     7.6  

Australian Dollar

     5.3  

Japanese Yen

     4.8  

Yuan Renminbi

     3.7  

Danish Krone

     3.3  
  

 

 

 

Total Investments

     100.0  

Other assets less liabilities

     (0.0 )* 
  

 

 

 

Net Assets

     100.0
  

 

 

 

 

*

Less than 0.1%